- Home
- NWAX vs AVIR Comparison
NWAX vs AVIR Comparison
Compare NWAX & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWAX | AVIR |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.0M | 434.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NWAX | AVIR |
|---|---|---|
| Price | $10.14 | $4.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 74.6K | ★ 330.7K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.68 | $2.78 |
| 52 Week High | $10.34 | $6.45 |
Technical Indicators
Market Signals| Indicator | NWAX | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 60.79 |
| Support Level | $10.06 | $4.14 |
| Resistance Level | $10.15 | $6.37 |
| Average True Range (ATR) | 0.03 | 0.21 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 72.00 | 82.72 |
Price Performance
Historical ComparisonAbout NWAX New America Acquisition I Corp. Class A Common Stock
New America Acquisition I Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which it refers to throughout this prospectus as its initial Business Combination.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.